RxDoctor Payments Data

Philomene Goueliani

Nurse Practitioner · Brooklyn, NYNPI 1891102885

Payments from drug & device makers

$1,291in general payments, 2019–2025

Across 48 payments — averaging $26.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$555
  • Ardelyx, Inc.$238
  • Axsome Therapeutics, Inc.$146
  • Novo Nordisk$96
  • AbbVie$73
  • AstraZeneca$65
  • plus $118 from 4 others

What the payments were for

  • Food & beverage$1,291100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,291 in reported general payments places this provider in the 85th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$12,885
Medicare patients
47
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala48$178,885
Diclofenac Sodium44$56,319
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl253$48,176
JubliaEfinaconazole30$39,186
Hydrocortisone Butyrate43$37,788
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate13$26,563
DescovyEmtricitabine/Tenofov Alafenam13$26,291
Diclofenac Potassium14$20,624
LinzessLinaclotide39$19,567
Breo ElliptaFluticasone/Vilanterol50$18,875
CreonLipase/Protease/Amylase19$16,644
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,891
SymbicortBudesonide/Formoterol Fumarate57$12,552
Oxiconazole Nitrate23$12,017
Diflorasone Diacetate15$9,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$555$205,17661 claims
AbbVieLinzess, Creon, Restasis$73$43,29770 claims
GSKBreo Ellipta, Trelegy Ellipta$21$31,76771 claims
AstraZenecaSymbicort$65$12,55257 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →